2024
The association between aberrant salience and psychotic experiences in general population twins, and genetic vulnerability as a modifier
Drukker M, Todor T, Bongaarts J, Broggi E, Kelkar M, Wigglesworth T, Verhiel K, van Leeuwen K, Koster M, Derom C, Thiery E, De Hert M, Menne-Lothmann C, Decoster J, Collip D, van Winkel R, Jacobs N, Guloksuz S, Rutten B, van Os J. The association between aberrant salience and psychotic experiences in general population twins, and genetic vulnerability as a modifier. BMC Psychiatry 2024, 24: 736. PMID: 39462331, PMCID: PMC11515186, DOI: 10.1186/s12888-024-06176-2.Peer-Reviewed Original ResearchConceptsAberrant salienceGeneral population twinsPsychotic experiencesGenetic vulnerabilityGeneral population samplePsychotic symptomsAssociated with psychotic experiencesUltra-high-risk patientsPositive symptom scalesSubclinical psychotic symptomsWhite noise taskEpisode psychosis patientsAssociated with psychosisPopulation samplePsychosis spectrumPsychosis patientsSymptom ScaleNoise taskSaliencePsychosisSevere endVulnerabilitySymptomsTaskAssociationCharacterizing the dynamics, reactivity and controllability of moods in depression with a Kalman filter
Malamud J, Guloksuz S, van Winkel R, Delespaul P, De Hert M, Derom C, Thiery E, Jacobs N, Rutten B, Huys Q. Characterizing the dynamics, reactivity and controllability of moods in depression with a Kalman filter. PLOS Computational Biology 2024, 20: e1012457. PMID: 39312537, PMCID: PMC11449358, DOI: 10.1371/journal.pcbi.1012457.Peer-Reviewed Original ResearchConceptsEcological momentary assessmentEcological momentary assessment dataMood statesMood disordersDepressive stateMood dynamicsFeatures of mood disordersCombination of ecological momentary assessmentsControl of moodSymptoms of depressionInternal emotional statesAlterations to interactionsPsychopathological featuresMomentary assessmentMoodEmotional statesDepressionEnvironmental stimuliThe European psychiatric association (EPA) – early career psychiatrists committee survey on trainees’ and early-career psychiatrists’ attitudes towards therapeutic drug monitoring (TDM) use and utility during antipsychotic treatment
Schoretsanitis G, Correll C, Agorastos A, Sanchez A, Erzin G, Grigoras R, Benussi M, Gondek T, Guloksuz S, Højlund M, Jerotic S, Kilic O, Metaj E, Sidhu D, Skandali N, Skuhareuski A, Tveito M, Wolthusen R, Communication and Publications E, Chumakov E, de Filippis R. The European psychiatric association (EPA) – early career psychiatrists committee survey on trainees’ and early-career psychiatrists’ attitudes towards therapeutic drug monitoring (TDM) use and utility during antipsychotic treatment. The World Journal Of Biological Psychiatry 2024, 25: 342-351. PMID: 38905131, DOI: 10.1080/15622975.2024.2367138.Peer-Reviewed Original ResearchConceptsEuropean Psychiatric AssociationAntipsychotic treatmentPsychiatrists' attitudesTherapeutic drug monitoringEarly-career psychiatristsExploratory factor analysisBenefit of therapeutic drug monitoringPsychiatric AssociationAntipsychoticsNegative expectationsAssociated with frequencyTDM useDrug monitoringTherapeutic drug monitoring useFactor analysisBeliefs of patientsHigh-income countriesLow-/middle-income countriesResponse varianceClinical benefitClozapineOutpatient settingLinear regression analysisClinical settingPsychiatrists
2023
Comprehensive dissection of prevalence rates, sex differences, and blood level-dependencies of clozapine-associated adverse drug reactions
van der Horst M, Meijer Y, de Boer N, Guloksuz S, Hasan A, Siskind D, Wagner E, consortium C, Müderrisoğlu A, Privat A, Bouhuis A, Hasan A, Jongkind A, Gonzalez-Pinto A, Santacana A, D'Agostino A, Ertugrul A, Yağcioğlu A, Crespo-Facorro B, Sanchez-Barbero B, Spuch C, Morgenroth C, de Pinedo C, Casetta C, Bousman C, Pantelis C, Ovejas-Catalán C, Garcia-Rizo C, Okhuijsen-Pfeifer C, Cohen D, Ristic D, Beld E, Repo-Tiihonen E, Wagner E, Jeger-Land E, Vilella E, Bekema E, Sepúlveda S, Seghi F, Wiedenmann F, Martini F, Serio F, Vairano F, Mercuriali G, Boido G, Yoca G, van Beek H, Gijsman H, Tuppurainen H, Everall I, Novakovic I, Zorrilla I, Erdoğan I, Sapienza J, Bogers J, Tiihonen J, Vázquez-Bourgon J, van Os J, Schneider-Thoma J, Luykx J, Grootens K, Mar-Barrutia L, Martorell L, Bak M, Spangaro M, de Vos M, de Koning M, Garriga M, Lähteenvuo M, Bosia M, van der Horst M, Babaoğlu M, Veereschild M, Manchia M, Edlinger M, Fuentes-Pérez P, Paribello P, Lopez-Pena P, Kahn R, Cavallaro R, Veerman S, Gutwinski S, Schreiter S, Ripke S, Baltanás T, Oviedo-Salcedo T, Hallikainen T, Görlitz T, Alink W, Ayhan Y, Okhuijsen-Pfeifer C, Luykx J. Comprehensive dissection of prevalence rates, sex differences, and blood level-dependencies of clozapine-associated adverse drug reactions. Psychiatry Research 2023, 330: 115539. PMID: 37988817, DOI: 10.1016/j.psychres.2023.115539.Peer-Reviewed Original ResearchConceptsAdverse drug reactionsClinical factorsDrug reactionsPrevalence ratesCommon adverse drug reactionsWeight gainSignificant weight gainMulti-center studyImproved treatment outcomesClozapine blood levelsClozapine monotherapyClozapine treatmentLower BMIBlood levelsTreatment outcomesHigh prevalencePrevalenceMean numberYounger participantsSex differencesParticipantsTreatmentComprehensive dissectionConstipationHypersalivationThe effect of duration of untreated psychosis (DUP) on the risk for hospitalization after admission to a first episode service
Ferrara M, Guloksuz S, Hazan H, Li F, Tek C, Sykes L, Riley S, Keshavan M, Srihari V. The effect of duration of untreated psychosis (DUP) on the risk for hospitalization after admission to a first episode service. Schizophrenia Research 2023, 260: 198-204. PMID: 37688984, DOI: 10.1016/j.schres.2023.08.005.Peer-Reviewed Original ResearchConceptsFirst-episode psychosis servicesLength of stayUntreated psychosisPsychiatric hospitalizationFirst-episode servicesDuration of hospitalizationIncidence rate ratiosNon-affective psychosisNew Haven areaPoisson regression modelsPatient characteristicsHospitalization ratesRecent onsetMedical recordsHospitalizationEffect of durationNegative binomial regressionSpecialized treatmentPsychosisRate ratioBinomial regressionAdmissionDUPEnrollmentFirst yearAddressing the Evidence to Practice Gap: What to Expect From International Antipsychotic Dose Reduction Studies in the Tapering Anti-Psychotics and Evaluating Recovery Consortium
Koops S, Allott K, de Haan L, Chen E, Hui C, Killackey E, Long M, Moncrieff J, Sommer I, Stürup A, Wunderink L, Begemann M, van der A J, Bakker P, Beer F, Begemann M, van Beveren N, Boonstra T, Brand B, Djordjevic M, Franke S, Gangadin S, Guloksuz S, Haan L, van ‘t Hag G, Hamers I, van der Heijden-Hobus I, Hoornaar R, Huizer K, Kikkert M, Koops S, Lokkerbol J, Marcelis M, Oomen P, van Os J, Rosema B, Sommer I, Smit F, Veling W, Voppel A, Albert N, Karlsen M, Nordentoft M, Speyer H, Stürup A, Allott K, Killackey E, O’Donoghue B, Stainton A, Cooper R, Conneely M, Grünwald L, Haynes N, Horowitz M, Mason J, Long M, Moncrieff J, Priebe S, Stansfeld J, Vasiliki G, Chen E, Hui C, Wunderink L, Liu C, Berna F, Foucher J. Addressing the Evidence to Practice Gap: What to Expect From International Antipsychotic Dose Reduction Studies in the Tapering Anti-Psychotics and Evaluating Recovery Consortium. Schizophrenia Bulletin 2023, 50: 5-8. PMID: 37625022, PMCID: PMC10754158, DOI: 10.1093/schbul/sbad112.Peer-Reviewed Original ResearchAssociations Between Childhood Area-Level Social Fragmentation, Maladaptation to School, and Social Functioning Among Healthy Youth and Those at Clinical High Risk for Psychosis
Ku B, Addington J, Bearden C, Cadenhead K, Cannon T, Compton M, Cornblatt B, Druss B, Gülöksüz S, Mathalon D, Perkins D, Tsuang M, Walker E, Woods S, Carrión R. Associations Between Childhood Area-Level Social Fragmentation, Maladaptation to School, and Social Functioning Among Healthy Youth and Those at Clinical High Risk for Psychosis. Schizophrenia Bulletin 2023, 49: 1437-1446. PMID: 37358832, PMCID: PMC10686327, DOI: 10.1093/schbul/sbad093.Peer-Reviewed Original ResearchConceptsClinical high riskHealthy comparisonsSocial functioningHigh riskPoor social functioningNorth American Prodrome Longitudinal StudyImportant risk factorRisk factorsPsychotic disordersEffective interventionsHealthy youthChildhoodLongitudinal studyAdulthoodPsychosisAssociationAdultsMaladaptationRiskSocial deficitsFurther researchFunctioningCommunity levelThe association between polygenic risk scores for mental disorders and social cognition: A scoping review
Fusar-Poli L, Rodolico A, Martinez M, Fichera C, Lin B, Basadonne I, Concerto C, Aguglia E, Guloksuz S, Signorelli M. The association between polygenic risk scores for mental disorders and social cognition: A scoping review. Journal Of Psychiatric Research 2023, 164: 389-401. PMID: 37418886, DOI: 10.1016/j.jpsychires.2023.06.029.Peer-Reviewed Original ResearchConceptsAutism spectrum disorderSocial cognitionMental disordersAttention deficit hyperactivity disorderReal-world functioningSC deficitsEmotion recognitionHyperactivity disorderSpectrum disorderPresent impairmentsPolygenic risk scoresCognitionFuture researchMolecular genetic riskSignificant difficultiesSpecific disordersDisordersUnaffected relativesGenetic riskRisk scorePeopleUnderstanding of mechanismsFunctioningEnvironmental risk factorsScoresThe Ethics of Risk Prediction for Psychosis and Suicide Attempt in Youth Mental Health
Smith W, Appelbaum P, Lebowitz M, Gülöksüz S, Calkins M, Kohler C, Gur R, Barzilay R. The Ethics of Risk Prediction for Psychosis and Suicide Attempt in Youth Mental Health. The Journal Of Pediatrics 2023, 263: 113583. PMID: 37353146, PMCID: PMC10828819, DOI: 10.1016/j.jpeds.2023.113583.Peer-Reviewed Original ResearchConceptsEthical implicationsDistinct ethical challengesEthical challengesEthicsInformed consentBroader discussionPolygenic risk scoresClinical utilityRisk scoreSuicide attemptsQuestionsYouth mental health settingsRisk-benefit balancePopulation-level screeningConsumer advertisingPotential clinical utilityMental health settingsAttemptConsentClinical questionsPredictive scoreHealth settingsNarrative literature reviewImplicationsLiterature reviewAn international research agenda for clozapine-resistant schizophrenia
Luykx J, Gonzalez-Diaz J, Guu T, van der Horst M, van Dellen E, Boks M, Guloksuz S, DeLisi L, Sommer I, Cummins R, Shiers D, Lee J, Every-Palmer S, Mhalla A, Chadly Z, Chan S, Cotes R, Takahashi S, Benros M, Wagner E, Correll C, Hasan A, Siskind D, Endres D, MacCabe J, Tiihonen J. An international research agenda for clozapine-resistant schizophrenia. The Lancet Psychiatry 2023, 10: 644-652. PMID: 37329895, DOI: 10.1016/s2215-0366(23)00109-8.Peer-Reviewed Original ResearchConceptsClozapine-resistant schizophreniaQuality of lifeTreatment optionsTreatment-resistant symptomsThird of patientsNew treatment optionsHealth care providersMiddle-income countriesFunctional outcomeInterventional studyUnmet needEpidemiological researchTranslational approachDiagnostic testsPatientsSchizophreniaHealth policyEarly detectionOptionsSymptomsDiagnosisTrialsImpact of personal beliefs about medical cannabis on physician recommendation practices: Results of an international survey
Syed S, Singh J, Elkholy H, Rojnić Palavra I, Tomicevic M, Eric A, Pinto da Costa M, Guloksuz S, Radhakrishnan R. Impact of personal beliefs about medical cannabis on physician recommendation practices: Results of an international survey. Asian Journal Of Psychiatry 2023, 85: 103634. PMID: 37257363, DOI: 10.1016/j.ajp.2023.103634.Peer-Reviewed Original ResearchAdjusting for population stratification in polygenic risk score analyses: a guide for model specifications in the UK Biobank
Lin B, Pries L, van Os J, Luykx J, Rutten B, Guloksuz S. Adjusting for population stratification in polygenic risk score analyses: a guide for model specifications in the UK Biobank. Journal Of Human Genetics 2023, 68: 653-656. PMID: 37188914, DOI: 10.1038/s10038-023-01161-1.Peer-Reviewed Original ResearchExamining the association between exposome score for schizophrenia and cognition in schizophrenia, siblings, and healthy controls: Results from the EUGEI study
Fusar-Poli L, Prachason T, Erzin G, Pries L, Brondino N, Politi P, Delespaul P, Kenis G, Luykx J, Lin B, Richards A, Akdede B, Binbay T, Altınyazar V, Yalınçetin B, Gümüş-Akay G, Cihan B, Soygür H, Ulaş H, Cankurtaran E, Kaymak S, Mihaljevic M, Andric-Petrovic S, Mirjanic T, Bernardo M, Mezquida G, Amoretti S, Bobes J, Saiz P, García-Portilla M, Sanjuan J, Escarti M, Santos J, Jiménez-López E, Arrojo M, Carracedo A, López G, González-Peñas J, Parellada M, Maric N, Atbaşoğlu C, Üçok A, Alptekin K, Saka M, Arango C, O'Donovan M, van Os J, Rutten B, Guloksuz S, investigators G. Examining the association between exposome score for schizophrenia and cognition in schizophrenia, siblings, and healthy controls: Results from the EUGEI study. Psychiatry Research 2023, 323: 115184. PMID: 37015164, DOI: 10.1016/j.psychres.2023.115184.Peer-Reviewed Original ResearchConceptsBenton Facial Recognition TestDegraded Facial Affect Recognition TaskWechsler Adult Intelligence Scale-Third EditionSchizophrenia spectrum disordersSocial cognitionCognitive domainsFacial affect recognition taskAffect recognition taskFacial Recognition TestCognitive impairmentRecognition testSpectrum disorderRecognition taskCross-sectional sampleHealthy controlsCognitionPsychosis spectrumShort versionUnaffected siblingsNeurocognitionEUGEI studySchizophreniaPerceptionImpairmentSiblingsAssociations between genetic liabilities to smoking behavior and schizophrenia symptoms in patients with a psychotic disorder, their siblings and healthy controls
Lin B, Vermeulen J, Bolhuis K, Chang X, Schirmbeck F, van Eijk K, investigators G, Alizadeh B, Bartels-Velthuis A, van Amelsvoort T, Bruggeman R, Cahn W, de Haan L, Rutten B, Guloksuz S, Luykx J, van Os J, Simons C, van Winkel R, Guloksuz S, Blankers M, van den Brink W, de Haan L, Luykx J. Associations between genetic liabilities to smoking behavior and schizophrenia symptoms in patients with a psychotic disorder, their siblings and healthy controls. Psychiatry Research 2023, 323: 115143. PMID: 36948018, DOI: 10.1016/j.psychres.2023.115143.Peer-Reviewed Original ResearchConceptsHealthy controlsSmoking behaviorPsychotic symptomsSchizophrenia symptomsUnaffected siblingsProspective cohort studySix-year followMental health symptomsSymptom dimensionsCohort studyRisk factorsDepressive symptomsPsychotic disordersPatientsPositive symptomsHealth symptomsNegative symptomsSimilar effect sizesSymptomsLinear mixed-effects modelsMixed-effects modelsGenetic riskMean numberPolygenic scoresOverall sampleAssociations Between Polygenic Risk Score Loading, Psychosis Liability, and Clozapine Use Among Individuals With Schizophrenia
Lin B, Pinzón-Espinosa J, Blouzard E, van der Horst M, Okhuijsen-Pfeifer C, van Eijk K, Guloksuz S, Peyrot W, Luykx J, Hasan A, Wagner E, Pantelis C, Everall I, Ayhan Y, Babaoğlu M, Bak M, Alink W, Beld E, Bouhuis A, Edlinger M, Erdoğan I, Gutwinski S, Hallikainen T, Jeger-land E, Lähteenvuo M, de Koning M, Morgenroth C, Müderrisoğlu A, Oviedo-Salcedo T, Schreiter S, Repo-Tiihonen E, Tuppurainen H, Veereschild M, Veerman S, de Vos M, Cohen D, Bogers J, Anıl Yağcıoğlu A, Tiihonen J, Ripke S, Bousman C, Van Beek H, Okhuijsen-Pfeifer C, van der Horst M, van Eijk K, Ertuğrul A, Yoca G, Görlitz T, Grootens K, Leucht S, Narang A, Schneider-Thoma J, Kahn R, Bekema E, Kleymann P, Luykx J, Alizadeh B, van Amelsvoort T, Cahn W, de Haan L, Schirmbeck F, Simons C, van Os J, Rutten B, van Winkel R. Associations Between Polygenic Risk Score Loading, Psychosis Liability, and Clozapine Use Among Individuals With Schizophrenia. JAMA Psychiatry 2023, 80: 181-185. PMID: 36542388, PMCID: PMC9857760, DOI: 10.1001/jamapsychiatry.2022.4234.Peer-Reviewed Original ResearchConceptsSchizophrenia spectrum disordersRisk ratioPolygenic risk scoresUnrelated healthy controlsRisk scorePRS-SCZClozapine useHealthy controlsOdds ratioCourse of illnessHigher likelihoodPsychosis liabilityClozapine prescribingClozapine prescriptionPharmacotherapy choicesClozapine treatmentObservational cohortMedication useAntipsychotic useAntipsychotic treatmentMAIN OUTCOMEMultinomial logistic regressionPrognostic studiesAntipsychoticsEarly interventionCoping and sleep quality in youth: An Experience Sampling study
Hagemann N, Kirtley O, Lafit G, Vancampfort D, Wampers M, Decoster J, Derom C, Gülöksüz S, De Hert M, Jacobs N, Menne‐Lothmann C, Rutten B, Thiery E, van Os J, van Winkel R, Wichers M, Myin‐Germeys I. Coping and sleep quality in youth: An Experience Sampling study. Journal Of Adolescence 2023, 95: 566-583. PMID: 36647754, DOI: 10.1002/jad.12137.Peer-Reviewed Original ResearchConceptsEmotion-focused copingExperience Sampling StudySleep qualityDaily sleep qualitySample of youthLocus of controlSampling studyUtrecht Coping ListPassive reactionNegative eventsDaily lifeFuture insomniaCopingSleep problemsQuality of sleepMental wellMental healthDisengagementYouthState locusIndividual presentStyleDecreased sleep qualitySleepPsychopathology
2022
Bidirectional relationships between cannabis use, anxiety and depressive symptoms in the mediation of the association with psychotic experience: further support for an affective pathway to psychosis
Radhakrishnan R, Pries LK, Erzin G, Have M, de Graaf R, van Dorsselaer S, Gunther N, Bak M, Rutten BPF, van Os J, Guloksuz S. Bidirectional relationships between cannabis use, anxiety and depressive symptoms in the mediation of the association with psychotic experience: further support for an affective pathway to psychosis. Psychological Medicine 2022, 53: 5551-5557. PMID: 36093677, PMCID: PMC10482707, DOI: 10.1017/s0033291722002756.Peer-Reviewed Original ResearchConceptsAnxiety/depressive symptomsDepressive symptomsCannabis usePE incidencePsychotic experiencesFirst longitudinal cohort studyNetherlands Mental Health SurveyLongitudinal cohort studyMental Health SurveyRole of cannabisBidirectional relationshipCohort studyHealth SurveyIncidence studyAffective symptomsSymptomsCannabisEducation statusLongitudinal studyPsychosisIncidenceAnxietyTemporal relationshipMediation analysisFurther supportLongitudinal alterations in mRNA expression of the BDNF neurotrophin signaling cascade in blood correlate with changes in depression scores in patients undergoing electroconvulsive therapy
Schurgers G, Walter S, Pishva E, Guloksuz S, Peerbooms O, Incio L, Arts B, Kenis G, Rutten B. Longitudinal alterations in mRNA expression of the BDNF neurotrophin signaling cascade in blood correlate with changes in depression scores in patients undergoing electroconvulsive therapy. European Neuropsychopharmacology 2022, 63: 60-70. PMID: 36067540, DOI: 10.1016/j.euroneuro.2022.07.183.Peer-Reviewed Original ResearchConceptsBrain-derived neurotrophic factorBDNF/TrkBExpression of BDNFSerum BDNF protein levelsBDNF protein levelsElectroconvulsive therapyDepression scoresMRNA expressionPeripheral bloodTreatment-resistant depressed patientsProtein levelsMechanism of actionAntidepressant effectsNeurotrophic factorDepressed patientsLongitudinal alterationsSevere depressionBlood correlatesEffective treatmentLongitudinal changesTrkBStudy periodNR3C1PatientsTherapyNongenetic Factors Associated With Psychotic Experiences Among UK Biobank Participants
Lin B, Pries L, Sarac H, van Os J, Rutten B, Luykx J, Guloksuz S. Nongenetic Factors Associated With Psychotic Experiences Among UK Biobank Participants. JAMA Psychiatry 2022, 79: 857-868. PMID: 35857297, PMCID: PMC9301596, DOI: 10.1001/jamapsychiatry.2022.1655.Peer-Reviewed Original ResearchThe association between cannabis use and facial emotion recognition in schizophrenia, siblings, and healthy controls: Results from the EUGEI study
Fusar-Poli L, Pries LK, van Os J, Radhakrishnan R, Pençe AY, Erzin G, Delespaul P, Kenis G, Luykx JJ, Lin BD, Akdede B, Binbay T, Altınyazar V, Yalınçetin B, Gümüş-Akay G, Cihan B, Soygür H, Ulaş H, Cankurtaran EŞ, Kaymak SU, Mihaljevic MM, Andric-Petrovic S, Mirjanic T, Bernardo M, Mezquida G, Amoretti S, Bobes J, Saiz PA, García-Portilla MP, Sanjuan J, Aguilar EJ, Santos JL, Jiménez-López E, Arrojo M, Carracedo A, López G, González-Peñas J, Parellada M, Maric NP, Atbaşoğlu C, Üçok A, Alptekin K, Saka MC, investigators G, Aguglia E, Arango C, Rutten BP, Guloksuz S. The association between cannabis use and facial emotion recognition in schizophrenia, siblings, and healthy controls: Results from the EUGEI study. European Neuropsychopharmacology 2022, 63: 47-59. PMID: 36055075, DOI: 10.1016/j.euroneuro.2022.08.003.Peer-Reviewed Original ResearchConceptsHealthy controlsCannabis useDegraded Facial Affect Recognition TaskPresent cross-sectional studyCross-sectional studyHigh genetic riskProgression of schizophreniaRegular cannabis useCognitive disturbancesRegular cannabisPsychosis riskPatientsSchizophreniaFacial emotion recognition performanceGenetic riskCannabisCurrent cannabisEUGEI studyLongitudinal studyAgeSiblingsAssociationRiskOnsetEffect relationship